Ocera drug rapidly reduces ammonia in liver cirrhosis trial

Friday, June 1, 2012 11:10 AM

Ocera Therapeutics of San Diego and the Hospital Universitari Vall d'Hebron Research Institute in Barcelona released preliminary data from an open label phase II study evaluating the overall effectiveness and safety of OCR-002 (ornithine phenylacetate) for the treatment of cirrhosis of the liver and upper GI bleeding.

Interim analysis of the first cohort of patients demonstrated that OCR-002, a novel injectable agent that removes toxic, circulating ammonia from the blood, is well tolerated and provided a rapid and durable ammonia reduction after 36 hours of treatment. By removing circulating ammonia, OCR-002 may treat or prevent hepatic encephalopathy (HE), a neuropsychiatric complication of acute liver failure associated with increased levels of circulating ammonia.

Furthermore, all 48 patients tolerated OCR-002 well for 5 days. There were no severe toxicities associated with the treatment and no incidence of HE, with patients doing well at the 30 day follow up. A rapid drop in ammonia from 80.01+/-13.44 uM at baseline to 41.95+/-4.99 uM was observed at 36 hours (ANOVA, p<0.05).

"Cirrhosis patients that present with acute upper gastrointestinal bleeding have a 30% chance of developing hepatic encephalopathy and require intensive care,” explained Dr. Juan Cordoba of Hospital Universitari Vall d'Hebron and the lead investigator of the study. “A medicine that can quickly remove the toxic ammonia may help prevent or reverse this life-threatening condition, minimize the need for intensive care and shorten hospitalization."

OCR-002, developed by Ocera Therapeutics, has received Orphan Drug designation in the U.S. and Europe and has Fast Track status in the U.S. OCR-002 is also being evaluated as a treatment of acute liver failure in the U.S.

Share:          
CWWeekly

April 13

Quintiles-Quest Diagnostics joint venture latest in CRO-central lab deals, more could be on horizon

Biotech companies raise record amount of capital in Q1

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs